

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7876970

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	PATENT SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
HARROW HEALTH, INC.	03/27/2023
HARROW IP, LLC	03/27/2023
RECEIVING PARTY DATA	
Name:	OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Street Address:	333 S. GRAND AVENUE, 28TH FLOOR
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90071
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8450311
CORRESPONDENCE DATA	
Fax Number:	(213)891-8763
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	rhonda.deleon@lw.com
Correspondent Name:	LATHAM & WATKINS LLP
Address Line 1:	355 SOUTH GRAND AVENUE
Address Line 4:	LOS ANGELES, CALIFORNIA 90071-1560
ATTORNEY DOCKET NUMBER:	074232-0001
NAME OF SUBMITTER:	RHONDA DELEON
SIGNATURE:	/Rhonda DeLeon/
DATE SIGNED:	03/30/2023
Total Attachments: 9	
source=Harrow - Patent Security Agreement Executed#page1.tif	
source=Harrow - Patent Security Agreement Executed#page2.tif	
source=Harrow - Patent Security Agreement Executed#page3.tif	
source=Harrow - Patent Security Agreement Executed#page4.tif	
source=Harrow - Patent Security Agreement Executed#page5.tif	
source=Harrow - Patent Security Agreement Executed#page6.tif	

source=Harrow - Patent Security Agreement Executed#page7.tif

source=Harrow - Patent Security Agreement Executed#page8.tif

source=Harrow - Patent Security Agreement Executed#page9.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of March 27, 2023 (“*Patent Security Agreement*”), made by each of the signatories hereto (the “*Patent Grantors*”), is in favor of Oaktree Fund Administration, LLC, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “*Administrative Agent*”).

W I T N E S S E T H:

WHEREAS, the Patent Grantors are party to a Security Agreement dated as of March 27, 2023 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the “*Security Agreement*”) in favor of the Administrative Agent, pursuant to which the Patent Grantors are required to execute and deliver this Patent Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Patent Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Patent Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lenders to enter into the Credit Agreement and to induce the Lenders to make their respective extensions of credit to the Borrower thereunder, each Patent Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in and to all of the following intellectual property now owned or controlled or at any time hereafter owned, controlled or acquired by such Patent Grantor or in which such Patent Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “*Patent Collateral*”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Patents owned or controlled by such Patent Grantor, including, without limitation, the registered and applied-for Patents of such Patent Grantor listed on **Schedule 1** attached hereto;

(b) to the extent not covered by **clause (a)**, all income, royalties and other payments now or hereafter due and payable with respect to any of the foregoing; and

(c) to the extent not covered by **clause (a)**, all causes of action for past, present or future infringement of any such Patents.

The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Patent Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Patent Grantor hereby authorizes and requests that the Commissioner of Patents record this Patent Security Agreement.

THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.


This Patent Security Agreement may be executed by one or more of the parties to this Patent Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Remainder of This Page Intentionally Left Blank.]

IN WITNESS WHEREOF, each Patent Grantor has caused this PATENT SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

GRANTORS:

**HARROW HEALTH, INC.
HARROW IP, LLC**

By: 
Name: Andrew R. Boll
Title: Chief Financial Officer and Secretary


Address for Notices:
c/o Harrow Health, Inc.
102 Woodmont Blvd., Suite 610
Nashville, TN 37205
Attn: Andrew R. Boll
Email: aboll@harrowinc.com


With a copy to:
Holland & Knight LLP
511 Union Street, Suite 2700
Nashville, TN 37219
Attn: Elle McCulty
Email: Elle.McCulty@hklaw.com

Accepted and Agreed:

OAKTREE FUND ADMINISTRATION, LLC,
as Administrative Agent

By: Oaktree Capital Management, L.P.
Its: Managing Member

By: 
Name: Lindsay Berz
Title: Managing Director

By: 
Name: Mary Gallegly
Title: Managing Director

Address:
Oaktree Fund Administration, LLC
333 S. Grand Avenue, 28th Floor
Los Angeles, CA 90071
Attn: Oaktree Agency
Email: oaktreeagency@glas.agency

With a copy to:
Oaktree Capital Management, L.P.
333 S. Grand Avenue, 28th Floor
Los Angeles, CA 90071
Attn: Stephen DeNelsky; Tim Markov
Email: SDeNelsky@oaktreecapital.com; TMarkov@oaktreecapital.com

PATENTS**Patents and Patent Applications**

Title	Country	Application No.	Patent No.	Owner
EPINEPHRINE COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	US	14/506,120	10,993,921	Harrow IP, LLC
EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	AU	2014329412A	2014329412B2	Harrow IP, LLC
EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	US	15/247,524	11,045,432	Harrow IP, LLC
EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	US	15/685,702	10,285,957	Harrow IP, LLC
INTRAOCULAR LENS COMPRISING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	US	15/066,731	9,814,673	Harrow IP, LLC
PHARMACEUTICAL COMPOSITIONS CONTAINING A FLUOROQUINOLONE ANTIBIOTIC DRUG	US	12/474,307	8,450,311	Harrow Health, Inc. ¹
PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	US	15/395,830	10,561,607	Harrow IP, LLC
PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF DRY EYE AND METHODS FOR FABRICATING AND USING THEREOF	US	16/523,059	10,695,351	Harrow IP, LLC
PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF DRY EYE AND METHODS FOR FABRICATING AND USING THEREOF	US	16/871,692	11,185,546	Harrow IP, LLC

¹ To be transferred to Harrow IP, LLC

PHARMACEUTICAL OPHTHALMIC COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	JP	2018-558268	6694525	Harrow IP, LLC
EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS	US	17/688,608		Harrow IP, LLC
EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS	WO	PCT/US2022/019167		Harrow IP, LLC
METHOD AND COMPOSITION FOR TREATING INFECTIOUS CONJUNCTIVITIS	US	17/550,802		Harrow IP, LLC
METHODS FOR INCREASING SHELF-LIFE OF OPHTHALMIC PHARMACEUTICAL COMPOSITIONS	US	17/881,092		Harrow IP, LLC
PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	BR	1120160015444		Harrow IP, LLC
TRYPAN BLUE COMBINATION AND METHOD FOR ADMINISTERING SAME	US	63/316,653		Harrow IP, LLC
EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	US	17/330,023	20210275471	Harrow IP, LLC
EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	US	17/384,373	20210346318	Harrow IP, LLC; Jointly owned with inventor John Scott Karolchyk
MYDRIATIC COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	WO	PCT/US2021/062643	WO2022132567A1	Harrow IP, LLC
PHARMACEUTICAL COMPOSITIONS FOR TREATING PRESBYOPIA AND METHODS FOR FABRICATING THEREOF	CA	3138510		Harrow IP, LLC
PHARMACEUTICAL COMPOSITIONS FOR TREATING PRESBYOPIA AND METHODS FOR FABRICATING THEREOF	EP	20802398.6		Harrow IP, LLC
Carboxyvinyl polymer-containing nanoparticle suspensions	US	12/957,864	8921337	Harrow IP, LLC
Carboxylvinyl polymer-containing nanoparticle suspensions	US	14/539,996	9662398	Harrow IP, LLC
Topical nepafenac formulations	US	11/292,484	7834059	Harrow IP, LLC

Topical nepafenac formulations	US	12/888,631	8071648	Harrow IP, LLC
Topical nepafenac formulations	US	13/253,648	8324281	Harrow IP, LLC
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	US	12/401,168	8128960	Harrow IP, LLC
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	US	13/352,009	8211880	Harrow IP, LLC
OPHTHALMIC COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF TWO POLYMERS ²	US	11/673,070	7,947,295	Harrow IP, LLC
ANTIBACTERIAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	EP	21852657.2		Harrow IP, LLC
ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF	HK	62022052844.7		Harrow IP, LLC
PHARMACEUTICAL FORMULATIONS OF TRANEXAMIC ACID AND THEIR USE	US	14/325,630	9,301,936	Harrow IP, LLC
PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES, AND THEIR USE	US	14/307,773	9,849,133	Harrow IP, LLC
PYRIMETHAMINE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	US	16/433,679	10,660,891	Harrow IP, LLC
PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES, AND THEIR USE	US	15/620,430	10,383,875	Harrow IP, LLC
ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF	US	16/250,711	11,338,018	Harrow IP, LLC
ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF	US	16/774,415	11,534,481	Harrow IP, LLC

² Patent is licensed from Harrow IP, LLC to Novartis.

PYRIMETHAMINE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	US	16/852,954	11,266,615	Harrow IP, LLC
ANTI-FUNGAL COMPOSITIONS FOR TREATING NAILS AND METHODS FOR FABRICATING AND USING THEREOF	US	16/026,542	10,426,744	Harrow IP, LLC
PACKAGED COMPOSITIONS COMPRISING HYPOCHLOROUS ACID AND MENTHOL AND METHODS OF MAKING THEREOF	US	18/078,350		Harrow IP, LLC
ANTIBACTERIAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	US	18/019,580		Harrow IP, LLC
OPHTHALMIC DYE COMPOSITION AND METHOD FOR ADMINISTERING SAME	US	18/117,126		Harrow IP, LLC
EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS	WO	PCT/US2023/063588		Harrow IP, LLC
MYDRIATIC COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	WO	PCT/US2021/062643		Harrow IP, LLC
EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS	WO	PCT/US2022/019167		Harrow IP, LLC
METHOD AND COMPOSITION FOR TREATING INFECTIOUS CONJUNCTIVITIS	WO	PCT/US2022/052728		Harrow IP, LLC
Pharmaceutical Formulations For Treating Glaucoma And Methods For Fabricating And Using Thereof	US	15832169	20180169092	Harrow IP, LLC
Pharmaceutical Compositions For Anesthesiological Applications	KR	KR20187000815A	KR1964571B1	Harrow Health, Inc. ³
Pharmaceutical formulations of xanthine or xanthine derivatives, and their use	AU	AU2018282741A	AU2018282741A1	Harrow IP, LLC
Pyrimethamine-based pharmaceutical compositions and methods for fabricating thereof	AU	AU2019280828A	AU2019280828A1	Harrow IP, LLC
Pharmaceutical Formulations Of Xanthine Or Xanthine Derivatives For Treating Dupuytren's Contracture	CA	CA2973087A	CA2973087C	Harrow IP, LLC
Pharmaceutical Ophthalmic Compositions And Methods For Fabricating Thereof	CA	CA3023243A	CA3023243C	Harrow IP, LLC

³ To be transferred to Harrow IP, LLC

Pharmaceutical Compositions For Intraocular Administration And Methods For Fabricating Thereof	CA	CA3119363A	CA3119363A1	Harrow IP, LLC
Pharmaceutical Compositions For Treating Presbyopia And Methods For Fabricating Thereof	CA	CA3138510A	CA3138510A1	Harrow IP, LLC
Adrenocorticotropic Hormone-Based Pharmaceutical Formulations And Methods For Fabricating And Using Thereof	EP	EP2020741089A	EP3911350A4	Harrow IP, LLC
Pharmaceutical Compositions For Treating Presbyopia And Methods For Fabricating Thereof	EP	EP2020802398A	EP3965732A1	Harrow IP, LLC
Curcumin-Based Pharmaceutical Compositions And Methods For Fabricating Thereof	HK	HK2019128205A	HK40012045A	Harrow IP, LLC
Adrenocorticotropic Hormone-Based Pharmaceutical Formulations And Methods For Fabricating And Using Thereof	HK	HK20226052844A	HK40063684A	Harrow IP, LLC
Mydriatic Compositions And Methods For Fabricating Thereof	PCT	WO2021US62643A	WO2022132567A1	Harrow IP, LLC
PHARMACEUTICAL OPHTHALMIC COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	JP	2018-558268	6694525	Harrow IP, LLC
EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS	PCT	PCT/US2022/019167		Harrow IP, LLC
ANTIBACTERIAL COMPOSITIONS AND METHODS FOR FABRICATING THEREOF	PCT	PCT/US2021/044518	2022031830	Harrow IP, LLC
PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF	BR	1120160015444		Harrow IP, LLC